Numerous clinical studies have shown that the serotonergic system also degenerates in
patients with Parkinson's disease. The causal role of this impairment in Parkinson's …

Abstract Serotonergic (5-HT) neurons degenerate in Parkinson's disease. To determine the
role of this 5-HT injury—besides the dopaminergic one in the parkinsonian symptomatology …

It is now widely accepted that compensatory mechanisms are involved during the early
phase of Parkinson's disease (PD) to delay the expression of motor symptoms. However, the …

The aim of this study was to investigate the causal role of an early serotonin injury on
parkinsonian-like motor symptomatology. Monkeys were pretreated with 3, 4 …

Parkinson's disease (PD) is characterized by dopaminergic neurodegeneration in the
substantia nigra and dopamine depletion in the striatum. Non-dopaminergic systems are …

Neurological disorders in humans can be modeled in animals using standardized
procedures that recreate specific pathogenic events and their behavioral outcomes. The …

Animal experimentation in the Parkinson's disease (PD) field is a classic example of how the
use of animal models to study diseases can have a significant impact on human health …

Abstract Purpose In the 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease
(PD), it is important to determine lesion severity. This evaluation can be performed in vivo …

The neurotoxin MPTP can damage dopamine systems in the brains of rodents, cats, or
monkeys, and is therefore widely used to model degenerative processes that underlie …

Loss of dopamine in the nigrostriatal system causes a severe impairment in motor function in
patients with Parkinson's disease and in experimental neurotoxic models of the disease. We …